Late last year, the therapy developers dosed their first patient following positive preclinical data demonstrating safety and ...

Chronic muscle inflammation in Duchenne muscular dystrophy (DMD) is driven by both infiltrating and resident macrophages, the latter stimulated by CSF-1 produced by fibro/adipogenic progenitors.

From STAT’s Adam Feuerstein: The FDA informed Capricor Therapeutics that a meeting of outside experts will be convened to ...

Receives regulatory authorization in the EU for ELEVATE-44-201, a Phase 1/2 MAD clinical study of ENTR-601-44 in patients living with Duchenne muscular dystrophy who are amenable to exon 44 skipping – ...

The CHMP recommends conditional marketing authorization for Duvyzat to treat Duchenne muscular dystrophy in patients aged 6 ...

Gene therapy has emerged as a promising approach to previously untreatable conditions, including Duchenne muscular dystrophy (DMD), a progressive disorder caused by DMD mutations that leads to early ...

plans to convene a panel of outside experts before deciding on the company's cell therapy for a heart condition related to Duchenne muscular dystrophy (DMD). Reuters, the news and media division ...

provides statistically and clinically meaningful treatment benefits in individuals with Duchenne muscular dystrophy (DMD) If approved by the European Commission, Duvyzat will be available for ...

The purpose of this report is to re-evaluate such a therapeutic program in muscular dystrophy when the drugs are used singly, in combination and with or without exercise. Objective serial ...